Figure 2.
Incidence rates for major adverse cardiovascular events after month 4 according to ranges of low-density lipoprotein cholesterol achieved at month 4 in the alirocumab group and in propensity score–matched patients from the placebo group. ALI indicates alirocumab; ARR, absolute risk reduction; PBO, placebo; and PSM, propensity score-matched.